NasdaqGM:TNGXBiotechs
How Leadership Shuffle, Pivotal Trial Plans And Pan-RAS Deal At Tango Therapeutics (TNGX) Has Changed Its Investment Story
Tango Therapeutics recently outlined leadership changes, including appointing Malte Peters as CEO and moving Barbara Weber to Executive Chair, alongside plans for pivotal trials and a pan-RAS supply agreement, while also granting equity awards to its new CFO and another employee under its 2023 Inducement Plan.
These developments highlight how Tango’s evolving leadership structure and long-term incentive grants are being aligned with upcoming clinical milestones and partnership...